Sublingual immunotherapy: What have we learnt from the 'big trials'?

Current Opinion in Allergy and Clinical Immunology

Volumn 8, Issue 6, 2008, Pages 577-584

  Durham, Stephen R ^a,b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Efficacy; Rhinoconjunctivitis; Safety; Sublingual immunotherapy

Indexed keywords

ALUTARD; ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; GRASS POLLEN EXTRACT; GRASS POLLEN VACCINE; ORALAIR; PHLEUM PRATENSE EXTRACT; PLACEBO; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; CHILD CARE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; HAY FEVER; HUMAN; IMMUNOTHERAPY; MOUTH DISEASE; ORAL PRURITUS; ORAL SWELLING; PHLEUM PRATENSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, SUBLINGUAL; ADULT; ALLERGENS; ANTIGENS, PLANT; CHILD; CLINICAL TRIALS, PHASE III AS TOPIC; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; HUMANS; IMMUNE TOLERANCE; PLANT EXTRACTS; RHINITIS, ALLERGIC, SEASONAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 56749096284     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3283196764     Document Type: Review

References (47)

1. Bousquet J, Lockey R, Malling HJ, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO position paper. Allergy 1998; 53 (Suppl 44):1-42.
2. Passalacqua G, Durhan SR. Allergic rhinitis and Its impact on asthma: immunotherapy update. J Allergy Clin Immunol 2007; 119:881-891.
3. Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. EAACI, Immunotherapy Task Force. Standards for practical allergen-specific immunotherapy. Allergy 2006; 61 (Suppl 82):1-20.
4. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60:4-12.
5. Radulovic S, Calderon M, Wilson S, Durham SR. Sublingual immunotherapy for allergic rhinitis: an updated Cochrane systematic review and meta-analysis. Allergy 2007; 62 (s83):167-551.
6. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007:CD001936.
7. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003:CD001186.
8. Durham SR, Walker SM, Varga EM, et al. Long term clinical efficacy of grass pollen immunotherapy. N Engl J Med 1999; 341:468-475.
9. Pajno GB, Barberio G, De Luca FR, et al. Prevention of new sensitisations in asthmatic children monosensitised to house dustmite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392-1397.
10. Jacobsen L, Niggeman B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62: 943-948.
11. Cox LS, Larenas Linneman D, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117:10021-10035.
12. Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006; 61:1162-1172.
13. Canonica GW, Baegna Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62:17-24.
14. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:802-809.
15. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 18:434-440. A large randomized controlled trial of grass allergen tablets for comparison with Didier et al. [17••]. Results are very similar.
16. Dahl R, Kapp A, Colombo G, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008; 121:512-518. A large randomized controlled trial of grass allergen tablets for comparison with Didier et al. [17••].
17. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120:1338-1345. Reports results of a large randomized controlled trial of grass allergen tablets for comparison with Dahl et al. [15•, 16•]. Results are very similar.
18. Frew AJ, Powell RJ, Corrigan CJ, Durham SR, UK Immunotherapy Study group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:319-325.
19. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006; 61:181-184.
20. Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy 2007; 62:958-961.
21. Durham SR, Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy 2007; 62:954-957.
22. Rak S, Yang WH, Pedersen MR, Durham SR. Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual Life Res 2007; 16:191-201.
23. Larsen T, Poulsen L, Melac M, et al. Safety and tolerability of grass tablets in sublingual immunotherapy (SLIT): a phase I study. Allergy 2006; 61:1173-1176.
24. Powell RJ, Frew AJ, Corrigan CJ, Durham SR. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. Allergy 2007; 62:1335-1338.
25. Wilson A, O'Byrne P, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004; 116:338-344.
26. Malling H, Weeke B. Immunotherapy: position paper of the European Academy of Allergy and Clinical Immunology. Allergy 1993; 48:S9-S35.
27. Di Rienzo V, Marcucci F, Puccinelli F, et al. Longlasting effect of sublingual immunotherapy in children with asthma due to house dust mite allergy: a 10-year prospective study. Clin Exp Allergy 2003; 33:206-210.
28. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004; 114:851-857.
29. Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomised controlled study:. Ann Allergy Asthma Immunol 2008; 101:206-211.
30. Röder E, Berger MY, de Groot H, van Wijk RG. Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: systematic review. Pediatr Allergy Immunol 2008; 19:197-207.
31. Penagos M, Compalati E, Tarantini F, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006; 97:141-148.
32. Penagos M, Passalacqua G, Compalati E, et al. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008; 133:599-609.
33. Röder E, Berger MY, Hop WC, et al. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol 2007; 119:892-898.
34. Horiguchi S, Okamoto Y, Yonekura S, et al. A randomized controlled trial of sublingual immunotherapy for Japanese cedar pollinosis. Int Arch Allergy Immunol 2007; 146:76-84.
35. Alvarez-Cuesta E, Berges-Gimeno P, González-Mancebo E, et al. Sublingual immunotherapy with a standardized cat dander extract: evaluation of efficacy in a double blind placebo controlled study. Allergy 2007; 62:810-817.
36. Nettis E, Colanardi MC, Soccio AL, et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. Br J Dermatol 2007; 56:674-681.
37. Werfel T, Breuer K, Rueff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitisation to house dust mites: a multicentre, randomised dose-response study. Allergy 2006; 61:202-205.
38. Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitised children with atopic dermatitis: a randomised double-blind placebo-controlled study. J Allergy Clin Immunol 2007; 120:164-170.
39. Severino MG, Cortellini G, Bonadonna P, et al. Sublingual immunotherapy for large local reactions caused by honey bee sting: a double-blind placebo-controlled trial. J Allergy Clin Immunol 2008; 122:44-48. Sublingual immunotherapy with bee venom extract reduced IgE-associated large local reactions. Provides 'proof of principle' for studies of the sublingual route for venom sting anaphylaxis.
40. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007; 62:567-568.
41. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008; 63: 374.
42. Moingeon M, Batard T, Fadel R, et al. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61:51-65.
43. Novak N, Haberstok J, Bieber T, Allam JP. The immune privelege of the oral mucosa. Trends Mol Med 2008; 14:191-198.
44. Savolainen J, Nieminen K, Laaksonen K, et al. Allergen-induced in vitro expression of IL-18, SLAM and GATA-3 mRNA in PBMC during sublingual immunotherapy. Allergy 2007; 62:949-953.
45. Bohle B, Kinaciyan T, Gerstmayr M, et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007; 120:707-713. This study supports the role of regulatory T cells in the mechanism of sublingual immunotherapy, as previously observed for subcutaneous route.
46. Allam JP, Peng WM, Appel T, et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 2008; 121:368-374. Novel functional study of Langerhans cells purified from human oral mucosa. The study emphasizes the importance of local immune regulation, which may be relevant to the mechanism of sublingual immunotherapy.
47. Mascarell L, Lombardi V, Louise A, et al. Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells. J Allergy Clin Immunol 2008; 122:603-609.